Your browser doesn't support javascript.
loading
Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases.
Clark, James D; Flanagan, Mark E; Telliez, Jean-Baptiste.
Afiliación
  • Clark JD; Pfizer Immunosciences , 200 CambridgePark, Cambridge, Massachusetts 02140, United States.
J Med Chem ; 57(12): 5023-38, 2014 Jun 26.
Article en En | MEDLINE | ID: mdl-24417533
ABSTRACT
The Janus kinases (JAKs) are a family of intracellular tyrosine kinases that play an essential role in the signaling of numerous cytokines that have been implicated in the pathogenesis of inflammatory diseases. As a consequence, the JAKs have received significant attention in recent years from the pharmaceutical and biotechnology industries as therapeutic targets. Here, we provide a review of the JAK pathways, the structure, function, and activation of the JAK enzymes followed by a detailed look at the JAK inhibitors currently in the clinic or approved for these indications. Finally, a perspective is provided on what the past decade of research with JAK inhibitors for inflammatory indications has taught along with thoughts on what the future may hold in terms of addressing the opportunities and challenges that remain.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Enfermedades Autoinmunes / Inhibidores de Proteínas Quinasas / Quinasas Janus / Inflamación / Antiinflamatorios Límite: Animals / Humans Idioma: En Revista: J Med Chem Asunto de la revista: QUIMICA Año: 2014 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Enfermedades Autoinmunes / Inhibidores de Proteínas Quinasas / Quinasas Janus / Inflamación / Antiinflamatorios Límite: Animals / Humans Idioma: En Revista: J Med Chem Asunto de la revista: QUIMICA Año: 2014 Tipo del documento: Article País de afiliación: Estados Unidos